First participant randomized in a Roche Phase III study
HMRG randomizes the first participant in a Roche-sponsored Phase III study — the first trial run in our newly expanded Hamilton research suites.
Read the announcementFrom the site
News & milestones
Study activations, enrollment firsts, and site developments — as they happen at 304 Victoria Avenue North.
-
-
Screening opens and fills within 72 hours
Roche activated HMRG's site on May 4, 2026 for a Phase III study. Screening opened the next day, and every May slot filled within 72 hours.
Read the announcement -
Initiation visit completed for a Roche Phase III study
Roche and its CRO completed the site initiation visit at 304 Victoria Avenue North: protocol training, systems access, and facility review ahead of activation.
Read the announcement
Follow the work
Milestones land here first — and on LinkedIn. Sponsors and CROs evaluating HMRG for an upcoming program can request feasibility information any time.